1Huang SP,Heng XP,Qiu CX,et al.Investigation and thinking about traditional Chinese medicine interfering cardiovascular risk factors in obese T2DM[J].Chin J Tradit Chin Med Pharm(中华中医药杂志),2009,24(8):1079-1084.
2Haverkate F,Tompson SG,Pyke SDM,et al.Production of C-reactive protein and risk of coronary events in stable and unstable angina[J].Lancet,1997,349(4):4622465.
3FDA Center for Devices and Radiological Health.Review Criteria for Assessment of C-Reactive Protein(CRP),High Sensitivity C-Reactive Protein(hsCRP)and Cardiac C-Reactive Protein(cCRP)Assays[S].Guidance for Industry and FDA Staff,2005.
8Pearson TA.Markers of inflammation and cardiovascular disease:application to clinical and public health practice:a statement for health care professions from the Centers for Disease Control and Prevention and the American Heart Association[J].Circulation,2003,107(3):499-511.
9Paul MR.Clinical application of C-reactive Protein for Carliovascuiar Disease Detection and Prevention[J].Circulation,2003,107(3):363-369.
10Wilson PW,Gostino DA,Levyd RB,et al.Prediction of coronary heart disease using risk factor categories[J].Circulation,1998,97:1837-1847.
9Esposito K, Pontillo A, Giugliano F, et al. Association of low interleukin-10 levels with the metabolic syndrome in obese women [ J ] . J Clin Endocrinol Metab, 2003 , 88 (3) : 1055-1058.
10van Exel E, Gussekloo J, de Craen A J M, et al. Low production capacity of interleukin-10 associates with the metabolic syndrome and Type 2 diabetes: the leiden 85-plus study[J]. Diabetes, 2002, 51 (4) : 1088-1092.
